Cubist Systematic Strategies LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 60.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,648 shares of the biotechnology company’s stock after buying an additional 14,224 shares during the period. Cubist Systematic Strategies LLC’s holdings in Exelixis were worth $927,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of EXEL. BlackRock Inc. raised its holdings in shares of Exelixis by 33,678.5% in the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after buying an additional 19,098,757 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Exelixis by 12.8% in the 1st quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock worth $514,339,000 after buying an additional 2,696,877 shares in the last quarter. Matrix Capital Management Company LP raised its holdings in shares of Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after buying an additional 1,225,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Exelixis in the 2nd quarter worth approximately $28,689,000. Finally, Meditor Group Ltd raised its holdings in shares of Exelixis by 5.5% in the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock worth $498,258,000 after buying an additional 1,046,000 shares in the last quarter. 79.20% of the stock is owned by institutional investors and hedge funds.

Shares of Exelixis, Inc. (EXEL) opened at 24.76 on Monday. Exelixis, Inc. has a 52-week low of $10.04 and a 52-week high of $29.50. The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of 125.05 and a beta of 1.92. The company’s 50-day moving average price is $26.24 and its 200-day moving average price is $23.95.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. During the same period in the previous year, the business earned ($0.15) earnings per share. The company’s revenue was up 173.1% on a year-over-year basis. Equities research analysts forecast that Exelixis, Inc. will post $0.27 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Cubist Systematic Strategies LLC Buys 14,224 Shares of Exelixis, Inc. (EXEL)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/16/cubist-systematic-strategies-llc-buys-14224-shares-of-exelixis-inc-exel.html.

A number of equities analysts have recently issued reports on the company. Cann reissued a “hold” rating on shares of Exelixis in a report on Monday. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Tuesday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Exelixis in a report on Monday, October 2nd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Exelixis in a research report on Monday, September 25th. Finally, Leerink Swann lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $34.00 to $28.00 in a research report on Friday, September 22nd. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Exelixis has a consensus rating of “Buy” and an average price target of $29.50.

In other Exelixis news, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $24.28, for a total transaction of $662,892.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher J. Senner sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total transaction of $2,679,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 970,152 shares of company stock valued at $25,923,457. Company insiders own 5.10% of the company’s stock.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.